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INVITED COMMENTARY
A. Ross Naylor, MD, FRCS, Leicester, United Kingdom
Despite being the most evidence-based procedure in surgical
history, carotid endarterectomy (CEA) maintains an unparalleled
reputation for controversy, none more so than the management of
recurrent stenosis. In the United Kingdom and Scandinavia, few
advocate intervention for recurrent stenosis unless the patient is
symptomatic. However, in mainland Europe and the United
States, there is a totally opposing viewpoint. Here the only debate
is whether treatment should be surgical or interventional. How is it
possible that the same scientific literature can be interpreted in such
a polarized way?
The paper by Stoner et al is typical of supporters of redo
surgery in its fundamental assumption that an asymptomatic, re-
current stenosis (ie, neointimal hyperplasia) confers an equivalent
stroke risk to atherosclerotic lesions. (Astute readers will have
observed, however, that Stoner et al did not have the same over-
whelming need to intervene on the 14 patients who developed
recurrent stenoses after redo surgery and who remained com-
pletely asymptomatic!) Thereafter, practice is usually justified by
the results of the Asymptomatic Carotid Atherosclerosis Study
(ACAS) and Asymptomatic Carotid Surgery Trial (ACST).1,2 This
is reflected by the authors’ comments that “reoperative CEA is an
accepted treatment for recurrent stenosis” and “reoperative CEA
has been affirmed as a safe and durable procedure.”Do these claims
stand up to close scrutiny? Are the authors’ results generalizable to
routine clinical practice?
Notwithstanding the inevitable problems associated with ret-
rospective studies (apparently no one lost to follow-up despite
some living far away, no clinical cardiac events, no data on patients
with recurrent stenoses not subjected to surgery, only two cranial
nerve injuries identified, and a nonstandard definition of perioper-
ative stroke), the principle results are extremely good and the
authors are to be commended. In this particular surgical unit, it
would be wrong to say that a policy of redo surgery was inappro-
priate in the face of a 1.9% complication rate.
However, I suspect that this very low level of risk, which is less
than that observed after primary CEA in ACAS and ACST, is
unlikely to be typical of overall clinical practice, and this observa-
tion is supported by the latest multistate audit by Kresowik et al.3
In the Kresowik et al series of 401 contemporary, redo CEAs in 10
states in the United States, the risk of perioperative death and
stroke was 5.7%. If this is a true reflection of practice—and it
probably is—and one assumes that the natural history (stroke risk)
of patients with recurrent disease is similar to that of asymptomatic
atherosclerotic patients, a simple reworking of the ACAS data
shows that only 25 ipsilateral strokes would be prevented at 5 years
by operating on 1,000 patients with restenosis where the periop-
erative risk is 5.7%.
Similarly, Stoner et al acknowledged the emergence of angio-
plasty as an alternative to redo CEA and cited the Stenting and
Angioplasty with Protection in Patients at High Risk for Endarter-
ectomy (SAPPHIRE) trial as showing noninferiority between the
two treatment strategies.4 In fact, 78% of SAPPHIRE patients
were asymptomatic (many were recurrent stenoses) in whom the
procedural risk averaged almost 6% for both treatment limbs. As
with the Kresowik et al study, this is a level of risk where there is no
natural history evidence that any intervention is warranted at all!
In summary, vascular units with results comparable to that of
Stoner et al can quite easily justify treating patients with recurrent
stenosis after CEA. However, those with complication rates 4%
cannot simply extrapolate the ACAS or ACST data to justify
intervention in patients with asymptomatic recurrent stenoses after
CEA. This statement clearly questions whether existing American
Heart Association (AHA) Guidelines should still apply. As Stoner
et al noted, the AHA advises surgeons that the stroke risk after
surgery for recurrent stenosis should be 10%.5 If we assume that
medically treated patients in ACAS and ACST do represent the
true natural history risk for patients with asymptomatic, recurrent
disease—which remains a generous assumption—surgeons per-
forming redo CEA with a 10% stroke risk will cause approximately
20 more strokes per 1,000 redo CEAs at 5 years than would have
occurred if patients had been left on medical treatment alone.
Stoner et al are to be commended for their results, but national
guidelines need to be revised.
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